Anti-HBc levels are associated with liver inflammation and response to peginterferon in chronic hepatitis B patients

BackgroundEmerging evidence suggests a pivotal role for B-cell responses in the natural history of chronic hepatitis B (CHB). Serum levels of antibodies to HBcAg (anti-HBc) vary across infection stages, but their role in predicting response to antiviral therapy is uncertain. MethodsAnti-HBc levels were assessed before peginterferon (PEG-IFN) therapy in CHB patients who either initiated de …

Continue reading Anti-HBc levels are associated with liver inflammation and response to peginterferon in chronic hepatitis B patients

Quantified integrated hepatitis B virus is related to viral activity in chronic hepatitis B patients

AbstractBackground & AimsThe hepatitis B virus (HBV) can integrate in the host genome of the hepatocyte and recent findings suggest that integrated HBV contributes to the persistent production of viral proteins. Here we quantified the levels of integrated HBV in chronic hepatitis B (CHB) patients, and analysed the relation between HBV integration, virological activity (plasma …

Continue reading Quantified integrated hepatitis B virus is related to viral activity in chronic hepatitis B patients

#Pradefovir Treatment in Patients with Chronic Hepatitis #B: Week 24 Results from a Multicenter, Double-blind, Randomized, Noninferiority, Phase 2 Trial

Pradefovir is a liver-targeted prodrug of adefovir, a nucleotide analog with antiviral activity against hepatitis B virus (HBV) DNA polymerase. This phase 2 study compared the efficacy and safety of oral pradefovir (30mg, 45mg, 60mg, and 75mg) versus tenofovir disoproxil fumarate (TDF; 300mg) and aimed to identify the most appropriate dose of pradefovir for the …

Continue reading #Pradefovir Treatment in Patients with Chronic Hepatitis #B: Week 24 Results from a Multicenter, Double-blind, Randomized, Noninferiority, Phase 2 Trial

Comparison of Novel Biomarkers with Conventional #HBV Markers among Untreated Adults with Chronic #Hepatitis B in North America

The clinical utility of two novel biomarkers, hepatitis B virus (HBV) RNA and hepatitis B core-related antigen (HBcrAg), as compared to conventional markers of HBV replication and disease activity is unclear. Untreated participants in the North American Hepatitis B Research Network Adult Cohort Study were categorized by chronic hepatitis B (CHB) phases based on HBsAg …

Continue reading Comparison of Novel Biomarkers with Conventional #HBV Markers among Untreated Adults with Chronic #Hepatitis B in North America

Serum hepatitis B #core‐related antigen level stratifies risk of disease progression in chronic #hepatitis B patients with intermediate viral load

Patients with chronic hepatitis B virus (HBV) infection are at risk of developing liver disease. Serum hepatitis B core‐related antigen (HBcrAg) is a new biomarker for intrahepatic templates for HBV replication.. ..A total of 1673 treatment‐naïve, non‐cirrhotic patients with negative hepatitis B e antigen (HBeAg) and alanine aminotransferase (ALT) level <40 U/L at baseline were …

Continue reading Serum hepatitis B #core‐related antigen level stratifies risk of disease progression in chronic #hepatitis B patients with intermediate viral load